ANAPTYSBIO INC. - COMMON STOCK

Anaptys Announces Participation in November Investor Conferences

01 Nov 2023 09:15:00 By Nasdaq GlobeNewswire

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

11 Oct 2023 09:15:00 By Nasdaq GlobeNewswire

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

09 Oct 2023 08:15:00 By Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

18 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

12 Sep 2023 09:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 16:15:09 By Nasdaq GlobeNewswire

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

31 Jul 2023 13:34:57 By Nasdaq GlobeNewswire

AnaptysBio Announces Participation in Upcoming Investor Conferences

30 May 2023 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

11 May 2023 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

02 May 2023 09:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

06 Apr 2023 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

27 Mar 2023 18:50:32 By Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

01 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

27 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Stock Repurchase Plan

13 Jan 2023 09:00:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

02 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

21 Nov 2022 13:56:39 By Nasdaq GlobeNewswire

AnaptysBio to Participate in Upcoming November Investor Conferences

09 Nov 2022 14:10:17 By Nasdaq GlobeNewswire